ABT
Abbott Laboratories
Abbott looks like a steadier diversified healthcare hold than a hard-rating opportunity, with the current valuation spread still moderate rather than wide.
Published note metadata
Archive viewLatest note event
New
Published Apr 10, 2026
Report updated
Apr 10, 2026
Current published rating
Hold
Published Apr 10, 2026
Current workspace signal
Buy (Low confidence)
Current workspace valuation context
Fair value
$102
Upside / Downside
+15.2 upside
Note context
Published note summaryTrend / quality cue
Model-base statements+5.5% revenue growth | 14.4% FCF margin
Model vs published view
Current model signal differs from the latest published analyst rating.